SONOMA PHARMACEUTICALS INC (SNOA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.33+0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
Sonoma is growing sales of Microcyn products in the US. Operating losses are shrinking, from -$1.1M to -$351K in 2026. Cash flow losses are improving, from -$2.0M to -$519K. The company signed new supply deals to support growth.
Sonoma still loses money and has negative cash flow. Sales growth is uncertain. The company faces management changes and legal risks. Debt issuance may pressure finances.
The market prices in ongoing losses and weak cash flow. There is no clear consensus on revenue growth or profit recovery. Our view sees some progress but high risk remains.
Breaks if: cash flow loss worsens or fails to improve by 2026-Q4
Breaks if: US Microcyn sales decline or stall over next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on expanding its Microcyn technology sales and improving operating income, which shows some positive momentum.
The market appears to be pricing in a challenging environment due to high risk and recent earnings misses. However, there is some expectation of growth in the healthcare sector, which could support SNOA if larger companies perform well.
Management is making progress on expanding sales and improving operating income, but cash flow from operations remains a concern. The recent decline in company quality also indicates potential challenges ahead.
The thesis hinges on the performance of sector bellwethers and the overall health of the economy. If larger healthcare companies continue to perform well, it could provide a tailwind for SNOA, but any signs of weakness could negatively impact the company.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue to grow sales of Microcyn technology-based products in the United States through manufacturing and supply agreements.
Newly stated in 2026-Q2. The company announced a Manufacturing and Supply Agreement with Kenvue Brands LLC for Microcyn technology-based products in the US, effective from October 2025 through March 2027. Revenue grew from $3.75M in 2025-Q4 to $6.41M in 2027-Q1, indicating growth in sales consistent with this priority.
“Entered into Manufacturing and Supply Agreement with Kenvue Brands LLC for Microcyn products in the US.”
Breaks if: operating losses worsen or fail to improve by 2026-Q4
In the next 1 to 3 years, SNOA's performance will depend on its ability to navigate risks while capitalizing on growth opportunities in the healthcare sector. Not investment advice.